Cable Hill Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | $277K | Buy |
4,348
+18
| +0.4% | +$1.21K | 0.03% | 157 |
|
|
2024
Q4 | $285K | Hold |
4,330
| – | – | 0.03% | 156 |
|
|
2024
Q3 | $304K | Sell |
4,330
-8
| -0.2% | -$669 | 0.03% | 146 |
|
|
2024
Q2 | $357K | Buy |
+4,338
| New | +$361K | 0.04% | 121 |
|
|
2023
Q4 | – | Sell |
-4,361
| Closed | -$386K | – | 115 |
|
|
2023
Q3 | $386K | Buy |
4,361
+31
| +0.7% | +$2.76K | 0.05% | 95 |
|
|
2023
Q2 | $375K | Hold |
4,330
| – | – | 0.05% | 102 |
|
|
2023
Q1 | $421K | Sell |
4,330
-313
| -7% | -$32.4K | 0.07% | 91 |
|
|
2022
Q4 | $481K | Buy |
4,643
+16
| +0.3% | +$1.5K | 0.09% | 75 |
|
|
2022
Q3 | $392K | Buy |
4,627
+297
| +7% | +$26.4K | 0.08% | 84 |
|
|
2022
Q2 | $359K | Hold |
4,330
| – | – | 0.09% | 90 |
|
|
2022
Q1 | $334K | Hold |
4,330
| – | – | 0.22% | 75 |
|
|
2021
Q4 | $383K | Hold |
4,330
| – | – | 0.08% | 98 |
|
|
2021
Q3 | $335K | Hold |
4,330
| – | – | 0.08% | 97 |
|
|
2021
Q2 | $361K | Hold |
4,330
| – | – | 0.09% | 91 |
|
|
2021
Q1 | $327K | Hold |
4,330
| – | – | 0.09% | 82 |
|
|
2020
Q4 | $380K | Hold |
4,330
| – | – | 0.1% | 68 |
|
|
2020
Q3 | $329K | Hold |
4,330
| – | – | 0.1% | 65 |
|
|
2020
Q2 | $534K | Hold |
4,330
| – | – | 0.18% | 39 |
|
|
2020
Q1 | $366K | Hold |
4,330
| – | – | 0.13% | 53 |
|
|
2019
Q4 | $366K | Hold |
4,330
| – | – | 0.11% | 60 |
|
|
2019
Q3 | $292K | Sell |
4,330
-70
| -2% | -$5.39K | 0.1% | 74 |
|
|
2019
Q2 | $377K | Hold |
4,400
| – | – | 0.13% | 66 |
|
|
2019
Q1 | $391K | Sell |
4,400
-54
| -1% | -$5K | 0.13% | 68 |
|
|
2018
Q4 | $379K | Hold |
4,454
| – | – | 0.15% | 59 |
|
|
2018
Q3 | $440K | Buy |
4,454
+54
| +1% | +$5.39K | 0.18% | 30 |
|
|
2018
Q2 | $414K | Hold |
4,400
| – | – | 0.17% | 31 |
|
|
2018
Q1 | $334K | Hold |
4,400
| – | – | 0.14% | 38 |
|
|
2017
Q4 | $397K | Sell |
4,400
-53
| -1% | -$4.61K | 0.17% | 40 |
|
|
2017
Q3 | $414K | Buy |
4,453
+53
| +1% | +$4.68K | 0.19% | 35 |
|
|
2017
Q2 | $398K | Hold |
4,400
| – | – | 0.21% | 23 |
|
|
2017
Q1 | $386K | Hold |
4,400
| – | – | 0.2% | 24 |
|
|
2016
Q4 | $364K | Hold |
4,400
| – | – | 0.16% | 31 |
|
|
2016
Q3 | $408K | Hold |
4,400
| – | – | 0.29% | 22 |
|
|
2016
Q2 | $359K | Hold |
4,400
| – | – | 0.26% | 22 |
|
|
2016
Q1 | $373K | Hold |
4,400
| – | – | 0.28% | 20 |
|
|
2015
Q4 | $461K | Hold |
4,400
| – | – | 0.33% | 16 |
|
|
2015
Q3 | $484K | Hold |
4,400
| – | – | 0.38% | 16 |
|
|
2015
Q2 | $602K | Buy |
4,400
+400
| +10% | +$49.6K | 0.45% | 12 |
|
|
2015
Q1 | $484K | Buy |
4,000
+1,000
| +33% | +$106K | 0.37% | 14 |
|
|
2014
Q4 | $271K | Buy |
+3,000
| New | +$249K | 0.27% | 22 |
|
Other funds holding BMRN
EIM
Cable Hill Partners's BMRN Position: Q1 2025 in Review
Cable Hill Partners increased its BioMarin Pharmaceuticals (BMRN) stake by 0.42% in Q1 2025, buying an estimated $1.21K and bringing the position to 4,348 shares worth $277K. The position accounts for 0.03% of the portfolio, ranked #157.
Cable Hill Partners first reported a position in BMRN in Q4 2014 and has held it in 40 quarters since. The position peaked at $602K in Q2 2015. 585 funds tracked by Wall St. Rank hold BMRN as of Q1 2025.
- Cable Hill Partners held 4,348 shares of BioMarin Pharmaceuticals worth $277K as of Q1 2025.
- Cable Hill Partners bought 18 BioMarin Pharmaceuticals shares in Q1 2025, an estimated $1.21K.
- BioMarin Pharmaceuticals made up 0.03% of Cable Hill Partners's portfolio in Q1 2025, its #157 holding.
- Cable Hill Partners first reported a position in BioMarin Pharmaceuticals in Q4 2014 and has held it in 40 quarters since.
- Cable Hill Partners's BioMarin Pharmaceuticals position peaked at $602K in Q2 2015.
- 585 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2025.
Based on Cable Hill Partners's 13F filing for Q1 2025, filed 2 May 2025.